Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Ongoing clinical trials involving direct targeting of KRAS. | Download Scientific Diagram
AMG 510 covalently modifies KRAS(G12C) in tumours and inhibits... | Download Scientific Diagram
RSC Medicinal Chemistry
Amgen unveils its KRas inhibitor in human clinical trials
Anti-Tumor Drug AMG 510 Shows Promise in Phase 1 Trial | City of Hope
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
AMG 510 combined with cytotoxic or targeted agents results in enhanced... | Download Scientific Diagram
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer: Trends in Pharmacological Sciences
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
KRAS Inhibitor Shows Promise in Early Trial - NCI
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Mixed data: AMG 510 in tumours with KRASG12C - Medical Conferences
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
Enhanced binding of AMG 510 to KRAS(G12C) results in improved... | Download Scientific Diagram
AMG 510 inhibits tumour growth of patient-derived xenografts, and... | Download Scientific Diagram
![PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/79175af828886f5f656cc808296d9057e16dceaa/2-Figure1-1.png "PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar")
PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Amgen's AMG 510 Targeted Cancer Therapy (NASDAQ:AMGN) | Seeking Alpha
Cancers | Free Full-Text | Targeting KRAS in Cancer: Promising Therapeutic Strategies
Cancer Drug Discovered with ALS Help Enters Phase 2 Trials - Biosciences Area
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation - ScienceDirect
AMG 510 inhibits KRAS(G12C) signalling and impairs viability a,... | Download Scientific Diagram
